Allopregnanolone for Brain Regeneration in Alzheimer's Disease
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial
This research explores if a natural brain compound called allopregnanolone can help regenerate brain cells and improve memory for people with early Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10851927 on NIH RePORTER |
What this research studies
We are exploring a new way to help the brain heal itself and reduce the effects of Alzheimer's disease. This approach uses allopregnanolone, a natural substance in the brain, which has shown promise in laboratory and animal models by helping new brain cells grow and improving thinking abilities. We believe this compound can also lessen the harmful changes seen in Alzheimer's. A previous small study found that this treatment was safe and well-tolerated, with no significant side effects.
Who could benefit from this research
Good fit: Ideal candidates are individuals diagnosed with mild cognitive impairment (MCI) due to Alzheimer's or early-stage Alzheimer's disease.
Not a fit: Patients with advanced Alzheimer's disease or other forms of dementia may not receive benefit from this specific approach.
Why it matters
Potential benefit: If successful, this treatment could help restore brain function and slow the progression of Alzheimer's disease.
How similar studies have performed: Preclinical studies have shown promising results in animal models, and a previous Phase 1 clinical trial indicated the treatment was safe and well-tolerated in humans.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Brinton, Roberta Eileen — University of Arizona
- Study coordinator: Brinton, Roberta Eileen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.